NYU study shows cancer cell biology may predict response to immunotherapy

Salk researchers find that stress hormones exhaust immune cells in humans and mice, beta-blockers can help

Salk Institute scientists discovered a relationship between killer T-cell exhaustion and the body’s sympathetic stress response, or “fight-or-flight,” in varying cancer types in mouse and human tissue samples.

September 29, 2023

Vol.49 No.36

In Brief

Michael J. Zelefsky named director of brachytherapy, vice chair for academic and faculty affairs at NYU

Michael J. Zelefsky is joining NYU Langone’s Perlmutter Cancer Center as director of brachytherapy and vice chair for academic and faculty affairs in NYU Grossman School of Medicine’s Department of Radiation Oncology.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Six-year outcomes from phase III CheckMate-227 show durable long-term survival with Opdivo + Yervoy in first-line treatment of mNSCLC

Six-year results from part 1 of the phase III CheckMate -227 trial demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression levels.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Rybrevant drug combo demonstrates durable PFS in second-line EGFR-mutated NSCLC in CHRYSALIS-2 cohort

Follow-up results from the phase Ib/II CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of Rybrevant (amivantamab-vmjw)—a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition—with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor, plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer and EGFR mutations, showed that the drug combination led to durable progression-free survival.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Kisqali reduced the risk of cancer recurrence while maintaining QOL in phase III study

Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

A multicenter phase II clinical study conducted by the SWOG Cancer Research Network suggests that combination ipilimumab and nivolumab can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to PD-1 inhibitors.

September 15, 2023

Vol.49 No.34

NYU study shows cancer cell biology may predict response to immunotherapy

YOU MAY BE INTERESTED IN

Salk researchers find that stress hormones exhaust immune cells in humans and mice, beta-blockers can help

Michael J. Zelefsky named director of brachytherapy, vice chair for academic and faculty affairs at NYU

Six-year outcomes from phase III CheckMate-227 show durable long-term survival with Opdivo + Yervoy in first-line treatment of mNSCLC

Rybrevant drug combo demonstrates durable PFS in second-line EGFR-mutated NSCLC in CHRYSALIS-2 cohort

Kisqali reduced the risk of cancer recurrence while maintaining QOL in phase III study

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

Renew today!

Subscriber content

Login